# Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

> **NCT03866187** · PHASE1,PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 236 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **BIOLOGICAL:** ChAd155-hIi-HBV low dose formulation
- **BIOLOGICAL:** ChAd155-hIi-HBV high dose formulation
- **BIOLOGICAL:** HBc-HBs/AS01B-4 low dose formulation
- **BIOLOGICAL:** HBc-HBs/AS01B-4 high dose formulation
- **BIOLOGICAL:** MVA-HBV low dose formulation
- **BIOLOGICAL:** MVA-HBV high dose formulation
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03866187
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-28
- **Primary completion:** 2024-10-07
- **Final completion:** 2024-10-07
- **Target enrollment:** 236 (ACTUAL)
- **Why stopped:** Following the primary phase (24 weeks post last vaccination) the predefined efficacy endpoint was not met. Noting the lack of efficacy and with the objective to prioritize participants' safety GSK has decided on the early termination of the study.
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03866187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03866187, "Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03866187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*